Maynard Um
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data Release
-
-
-
-
-
-
-
Bernstein SocGen Group Starts Revolution (RVMD) at Market Perform
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $185 at Mizuho
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $200 at Evercore ISI
-
-
-
-
-
-
-
Revolution (RVMD) Reiterated at Buy by Stifel Ahead of Numerous Stock-Moving Events
-
-
-
-
-
-
-
Revolution (RVMD) PT Lowered to $145 at Needham
-
-
-
-
-
-
-
Merck ends acquisition talks with Revolution Medicines - WSJ
-
418,470 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

